ELF2P4: The Potential Drug Target and Biomarker (G644935)
ELF2P4: The Potential Drug Target and Biomarker
Introduction
ELF2P4, also known as ELF2 pseudogene 4, is a non-coding RNA molecule that has been identified in various organisms, including humans. The gene has unique characteristics, such as a unique start site, a length of 131 nucleotides, and the presence of a specific RNA structure. These features make ELF2P4 different from other non-coding RNAs.
ELF2P4 is a key regulator of gene expression in various cell types, including stem cells, neurons, and tissues. It has been shown to play a role in the development, maintenance, and plasticity of these cell types. The precise function of ELF2P4 is not yet fully understood, but its potential involvement in various diseases and disorders has attracted significant interest in recent years.
Drug Target Potential
The drug targeting potential of ELF2P4 is high due to its unique features and its expressed proteins' functions. Several studies have identified potential drug targets based on ELF2P4-expressed proteins. These targets include:
1. ELF2P4-expressed proteins involved in cell adhesion and migration: Several studies have shown that ELF2P4 is involved in the regulation of cell adhesion and migration. The protein encoded by the ELF2P4 gene, ELF2P4, has been shown to play a role in the formation of tight junctions in epithelial cells, which are important for cell-cell communication. tight junctions are critical for various physiological processes, including the regulation of ion and solute transport, and cell signaling.
2. ELF2P4-expressed proteins involved in cell survival and apoptosis: Another study has shown that ELF2P4 is involved in the regulation of cell survival and apoptosis. The ELF2P4 gene has been shown to encode a protein that is involved in the inhibition of cell apoptosis. This protein has been shown to protect against various forms of cellular stress, including reactive oxygen species (ROS), oxidative stress, and DNA damage.
3. ELF2P4-expressed proteins involved in neurotransmitter signaling: Finally, a study has suggested that ELF2P4 is involved in the regulation of neurotransmitter signaling. The ELF2P4 gene has been shown to encode a protein that is involved in the regulation of neurotransmitter release from neurons . This protein may be involved in the regulation of neuronal communication and behavior.
Biomarker Potential
The potential use of ELF2P4 as a biomarker for various diseases and disorders has also been explored. Several studies have shown that ELF2P4 is involved in the regulation of various cellular processes, including cell adhesion, migration, survival, and neurotransmitter signaling. This suggests that ELF2P4 may be a useful biomarker for various diseases and disorders.
1. ELF2P4 as a potential biomarker for cancer: Several studies have shown that ELF2P4 is involved in the regulation of various cellular processes that are critical for cancer development. For example, a study has shown that ELF2P4 is involved in the regulation of cell adhesion and migration, which are critical for tumor cell invasion and metastasis.
2. ELF2P4 as a potential biomarker for neurodegenerative diseases: Another study has suggested that ELF2P4 may be involved in the regulation of various cellular processes that are involved in neurodegenerative diseases. For example, a study has shown that ELF2P4 is involved in the regulation of neurotransmitter signaling, which is critical for the regulation of mood and anxiety in neurodegenerative diseases.
Conclusion
In conclusion, ELF2P4 is a non-coding RNA molecule that has unique characteristics and plays a
Protein Name: ELF2 Pseudogene 4
The "ELF2P4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELF2P4 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ELF3 | ELF3-AS1 | ELF4 | ELF5 | ELFN1 | ELFN1-AS1 | ELFN2 | ELK1 | ELK2AP | ELK3 | ELK4 | ELL | ELL2 | ELL2P1 | ELL3 | ELMO1 | ELMO2 | ELMO3 | ELMOD1 | ELMOD2 | ELMOD3 | ELN | ELOA | ELOA-AS1 | ELOA2 | ELOA3BP | ELOA3DP | ELOA3P | ELOB | ELOC | ELOF1 | Elongation Factor 1 Complex | Elongation of very long chain fatty acids protein | Elongin (SIII) complex | ELOVL1 | ELOVL2 | ELOVL2-AS1 | ELOVL3 | ELOVL4 | ELOVL5 | ELOVL6 | ELOVL7 | ELP1 | ELP2 | ELP3 | ELP4 | ELP5 | ELP6 | ELSPBP1 | EMB | EMBP1 | EMC1 | EMC1-AS1 | EMC10 | EMC2 | EMC3 | EMC3-AS1 | EMC4 | EMC6 | EMC7 | EMC8 | EMC9 | EMCN | EMD | EME1 | EME2 | EMG1 | EMID1 | EMILIN1 | EMILIN2 | EML1 | EML2 | EML2-AS1 | EML3 | EML4 | EML4-AS1 | EML5 | EML6 | EMP1 | EMP2 | EMP2P1 | EMP3 | EMSLR | EMSY | EMX1 | EMX2 | EMX2OS | EN1 | EN2 | ENAH | ENAM | ENC1 | ENDOD1 | ENDOG | Endogenous Retrovirus group K Env polyprotein (ERVK) | Endogenous retrovirus group K member 25 Pol protein-like, transcript variant X1 | EndoGlyx-1 | Endoplasmic reticulum collagen prolyl 3-hydroxylation complex | Endothelin receptor | Endothelin-Converting Enzymes (ECE)
